

day, specifically by administering Compound (I) one to two times per day in a unit dosage form of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 mg. Obvious to try or experiment is not the standard under §103.

Applicant respectfully submits that the Background discussion fails to disclose or provide any suggestion to use the specifically recited components and to use them in the specifically recited amounts as provided in new claims 16-70.

In view of the foregoing amendments and remarks, Applicant respectfully submits that the presently claimed invention is patentable over the Background discussion at page 1, lines 6-18 of the subject specification and that subject application is in condition for allowance. If the Examiner has any remaining objections or concerns, the Examiner is respectfully requested to contact Applicant's undersigned attorney to resolve such issues and advance the case to issue.

INFORMATION DISCLOSURE STATEMENT

In compliance with the duty of disclosure under 37 C.F.R. §1.56, and in accordance with the practice under 37 C.F.R. §1.97, the Examiner's attention is directed to the documents listed on the enclosed Form PTO 1449. A copy of each of the listed documents is also enclosed. The filing of this Information Disclosure Statement should not be construed as an admission that any particular listed reference is effective prior art or discloses or renders obvious any aspect of the claimed invention.


This statement is being filed under the provisions of 37 C.F.R. §1.97(c)(2), before the mailing date of a Final Office action or before the mailing date of a Notice of Allowance. Please charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

This Amendment and Information Disclosure Statement is being filed together with Petition for Extension of Time. In the event that these papers

get separated, this constitutes a Petition for Extension of Time for the minimum period required to effect timely filing of this Amendment and Information Disclosure Statement, together with an authorization to charge any fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper to Deposit Account No. 19-2570.

Respectfully submitted,



Kathryn L. Sieburth
Attorney for Applicant
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property-UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone: (610) 270-5012
Facsimile: (610) 270-5090
N:\kls\cases\p31831c1\p31831C1 Response 11-13-02.doc